Liu Yong, Hou Jun-Huan, Li Qing, Chen Kui-Jun, Wang Shu-Nan, Wang Jian-Min
Intensive Care Unit, Suining Central Hospital, Deshengxi Road 127, Chuanshan District, Suining, 629000 Sichuan People's Republic of China.
Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, 400042 People's Republic of China.
Springerplus. 2016 Dec 12;5(1):2091. doi: 10.1186/s40064-016-3591-5. eCollection 2016.
Sepsis is one of the most common diseases that seriously threaten human health. Although a large number of markers related to sepsis have been reported in the last two decades, the diagnostic accuracy of these biomarkers remains unclear due to the lack of similar baselines among studies. Therefore, we conducted a large systematic review and meta-analysis to evaluate the diagnostic value of biomarkers from studies that included non-infectious systemic inflammatory response syndrome patients as a control group.
We searched Medline, Embase and the reference lists of identified studies beginning in April 2014. The last retrieval was updated in September 2016.
Ultimately, 86 articles fulfilled the inclusion criteria. Sixty biomarkers and 10,438 subjects entered the final analysis. The areas under the receiver operating characteristic curves for the 7 most common biomarkers, including procalcitonin, C-reactive protein, interleukin 6, soluble triggering receptor expressed on myeloid cells-1, presepsin, lipopolysaccharide binding protein and CD64, were 0.85, 0.77, 0.79, 0.85, 0.88, 0.71 and 0.96, respectively. The remaining 53 biomarkers exhibited obvious variances in diagnostic value and methodological quality.
Although some biomarkers displayed moderate or above moderate diagnostic value for sepsis, the limitations of the methodological quality and sample size may weaken these findings. Currently, we still lack an ideal biomarker to aid in the diagnosis of sepsis. In the future, biomarkers with better diagnostic value as well as a combined diagnosis using multiple biomarkers are expected to solve the challenge of the diagnosis of sepsis.
脓毒症是严重威胁人类健康的最常见疾病之一。尽管在过去二十年中已报道了大量与脓毒症相关的标志物,但由于研究之间缺乏相似的基线,这些生物标志物的诊断准确性仍不明确。因此,我们进行了一项大型系统评价和荟萃分析,以评估来自将非感染性全身炎症反应综合征患者作为对照组的研究中的生物标志物的诊断价值。
我们检索了2014年4月开始的Medline、Embase以及已识别研究的参考文献列表。最后一次检索于2016年9月更新。
最终,86篇文章符合纳入标准。60种生物标志物和10438名受试者进入最终分析。7种最常见生物标志物(包括降钙素原、C反应蛋白、白细胞介素6、髓系细胞表面表达的可溶性触发受体-1、可溶性髓系细胞触发受体-1、脂多糖结合蛋白和CD64)的受试者工作特征曲线下面积分别为0.85、0.77、0.79、0.85、0.88、0.71和0.96。其余53种生物标志物在诊断价值和方法学质量上表现出明显差异。
尽管一些生物标志物对脓毒症显示出中等或中等以上的诊断价值,但方法学质量和样本量的局限性可能会削弱这些发现。目前,我们仍然缺乏一种理想的生物标志物来辅助脓毒症的诊断。未来,有望通过具有更好诊断价值的生物标志物以及使用多种生物标志物的联合诊断来解决脓毒症诊断的挑战。